Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Retrospective financial analysis of a herpes zoster vaccination program from an independent community pharmacy perspective.

Wood HM, McDonough RP, Doucette WR.

J Am Pharm Assoc (2003). 2009 Jan-Feb;49(1):12-7. doi: 10.1331/JAPhA.2009.08030.

PMID:
19196591
2.

Effect of pharmacist intervention on herpes zoster vaccination in community pharmacies.

Wang J, Ford LJ, Wingate L, Uroza SF, Jaber N, Smith CT, Randolph R, Lane S, Foster SL.

J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):46-53. doi: 10.1331/JAPhA.2013.12019.

3.

Retrospective financial analysis of medication therapy management services from the pharmacy's perspective.

McDonough RP, Harthan AA, McLeese KE, Doucette WR.

J Am Pharm Assoc (2003). 2010 Jan-Feb;50(1):62-6. doi: 10.1331/JAPhA.2010.08154.

PMID:
20097640
4.

The Impact of Pharmacist Interventions on Herpes Zoster Vaccination Rates.

Eid DD, Meagher RC, Lengel AJ.

Consult Pharm. 2015 Aug;30(8):459-62. doi: 10.4140/TCP.n.2015.459.

PMID:
26260642
5.

Economic analysis of a herpes zoster vaccination program in 19 affiliated supermarket pharmacies.

Hedden MA, Kuehl PG, Liu Y.

J Am Pharm Assoc (2003). 2014 Jul-Aug;54(4):390-6. doi: 10.1331/JAPhA.2014.13140.

PMID:
24952742
6.

Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies.

Teeter BS, Garza KB, Stevenson TL, Williamson MA, Zeek ML, Westrick SC.

Vaccine. 2014 Sep 29;32(43):5749-54. doi: 10.1016/j.vaccine.2014.08.040. Epub 2014 Aug 27.

PMID:
25171848
7.

Retrospective financial analysis of wellness center from an independent community pharmacy perspective.

Kent K, McDonough RP, Dinges B, Doucette WR.

J Am Pharm Assoc (2003). 2006 Jul-Aug;46(4):447-52.

PMID:
16913387
8.

Advocating zoster vaccination in a community pharmacy through use of personal selling.

Bryan AR, Liu Y, Kuehl PG.

J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):70-7. doi: doi: 10.1331/JAPhA.2013.11097.

PMID:
23636159
9.

Three-year financial analysis of pharmacy services at an independent community pharmacy.

Doucette WR, McDonough RP, Mormann MM, Vaschevici R, Urmie JM, Patterson BJ.

J Am Pharm Assoc (2003). 2012 Mar-Apr;52(2):181-7. doi: 10.1331/JAPhA.2012.11207.

PMID:
22370381
10.

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.

van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE.

BMC Health Serv Res. 2010 Aug 13;10:237. doi: 10.1186/1472-6963-10-237.

11.

Improving pneumococcal and herpes zoster vaccination uptake: expanding pharmacist privileges.

Taitel MS, Fensterheim LE, Cannon AE, Cohen ES.

Am J Manag Care. 2013 Sep;19(9):e309-13.

PMID:
24449960
12.

Costs of adult vaccination in medical settings and pharmacies: an observational study.

Singhal PK, Zhang D.

J Manag Care Spec Pharm. 2014 Sep;20(9):930-6.

13.

Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.

Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P.

Vaccine. 2012 Jan 11;30(3):675-84. doi: 10.1016/j.vaccine.2011.10.036. Epub 2011 Nov 24.

PMID:
22120193
14.

A systematic review of the cost effectiveness of herpes zoster vaccination.

Szucs TD, Pfeil AM.

Pharmacoeconomics. 2013 Feb;31(2):125-36. doi: 10.1007/s40273-012-0020-7. Review.

PMID:
23335045
15.

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ.

Vaccine. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8.

PMID:
23306360
16.

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.

Sanford M, Keating GM.

Drugs Aging. 2010 Feb 1;27(2):159-76. doi: 10.2165/10489140-000000000-00000. Review.

PMID:
20104941
17.

Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination.

Di Legami V, Gianino MM, Ciofi degli Atti M, Massari M, Migliardi A, Tomba GS, Zotti C; Zoster Study Group.

Vaccine. 2007 Oct 23;25(43):7598-604. Epub 2007 Aug 15.

PMID:
17889410
18.

Cost-effectiveness of vaccination against herpes zoster.

de Boer PT, Wilschut JC, Postma MJ.

Hum Vaccin Immunother. 2014;10(7):2048-61. doi: 10.4161/hv.28670. Review.

19.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Rothberg MB, Virapongse A, Smith KJ.

Clin Infect Dis. 2007 May 15;44(10):1280-8. Epub 2007 Apr 3.

20.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
Items per page

Supplemental Content

Write to the Help Desk